Thermo Fisher Scientific Webinar
Procalcitonin – Optimal Clinical Application in Sepsis and to Assist in Antibiotic Decisions
At the conclusion of this session, the participant will be able to:
- Explain the regulation and kinetics of Procalcitonin and other inflammatory markers during sepsis
- Discuss strength and limitations of traditional parameters and novel markers, such as Procalcitonin in the diagnostic work-up of patients with suspicion of infection
- Detail the importance of early recognition of sepsis and early and adequate treatment (Sepsis bundles)
- Determine how Procalcitonin can be used for monitoring treatment response and antibiotic de-escalation in patients in and outside the ICU
- Describe the concept of Procalcitonin-aided antibiotic stewardship in sepsis in the ICU and respiratory tract infections in the Emergency
- Department and medical ward
Speakers AND MODERATORS:
Dr. Jan Friedrich - Moderator
Dr. Friedrich is Associate Professor of Medicine at the University of Toronto, and Medical Director of the Medical-Surgical Intensive Care Unit at St. Michael’s Hospital. He has a Doctor of Philosophy in Chemistry from Oxford University and received his MD magna cum laude from Harvard Medical School and Massachusetts Institute of Technology Division of Health Sciences and Technology. He went on to training in Internal Medicine and Critical Care Medicine, and then an MSc in Clinical Epidemiology, all at the University of Toronto. Dr. Friedrich is supported by a Canadian Institutes of Health Research (CIHR) Clinician-Scientist Award. His current research interests include the development and use of meta-analytic techniques, ARDS and sepsis (evaluation of therapies), and acute renal failure in ICU.
Prof. Dr. med. Philipp Schuetz
Dr. Schuetz, a co-author of the MOSES study, is chief physician of endocrinology, diabetes, clinical nutrition and internal medicine at University Hospital, department at the Kantonsspital Aarau in the emergency department and the Endocrine unit and is in charge of clinical studies focusing on clinical nutrition (EFFORT), as well as on improved triage and management of patients throughout their hospital stay with the use of novel biomarkers. He has completed extensive clinical research on hormones, “hormokines” and other biomarkers for better diagnostic and prognostic work up of patients with systemic infections, including two large landmark trials investigating Procalcitonin.